文献速递白血病造血干细胞移植与细胞治疗

比生群联合氟达拉滨和氯法拉滨作为成人难治或复发急性髓系白血病挽救治疗的开放标签I/II期研究

Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.
PubMed 文献 · Br J Haematol · 2025-08-01

这项开放标签I/II期研究评估比生群联合氟达拉滨和氯法拉滨在复发/难治性急性髓系白血病中的安全性与疗效。21例患者接受氟达拉滨10 mg/m2、氯法拉滨30 mg/m2和比生群250 mg/m2静脉给药4天。15例可评估疗效者中6例缓解,总缓解率40%,方案安全性可耐受,可能作为高危、经重度预处理患者的桥接治疗。

要点

  • 21例复发/难治AML患者接受比生群联合氟达拉滨和氯法拉滨治疗,中位年龄47岁,55%为女性。
  • 15例可评估疗效者中6例缓解(5例完全缓解,1例伴髓外病变者部分缓解),缓解率40%。
  • 10例出现肝毒性但均缓解,未观察到显著心脏毒性;6例因治疗开始30天内早期非复发死亡而无法评估疗效。

核心结论

  • 比生群联合氟达拉滨和氯法拉滨方案显示出可耐受的安全性,并在高危、经重度预处理的AML中具有作为桥接治疗的潜力。

研究设计与样本

  • 开放标签I/II期研究(NCT04989335),评估比生群联合氟达拉滨和氯法拉滨在复发/难治性AML中的安全性与疗效。
  • 共纳入21例患者,中位年龄47岁,55%为女性;16例为异基因造血干细胞移植后复发,6例伴髓外病变。
  • 给药方案为氟达拉滨10 mg/m2、氯法拉滨30 mg/m2和比生群250 mg/m2静脉给药4天。

主要发现

  • 21例中15例可评估疗效,6例因治疗开始30天内早期非复发死亡、未进行首次治疗后评估而无法评估疗效。
  • 15例可评估患者中6例缓解:5例达完全缓解,1例伴髓外病变者达部分缓解,缓解率40%。
  • 缓解为暂时性,但6例患者(包括4例接受第二次异基因造血干细胞移植者)在治疗后1-3个月内接受了异基因造血干细胞移植。
  • 10例出现肝毒性,但均缓解;未观察到显著心脏毒性。

临床怎么用

  • 原文结论认为该方案安全性可耐受,并具有作为高危、经重度预处理AML患者桥接治疗的潜力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bisantrene (Bis), an anthracene derivative with topoisomerase-II inhibitory activity and low cardiotoxicity, may enhance its efficacy when combined with nucleoside analogues such as clofarabine (Clo) and fludarabine (Flu) in preclinical acute myeloid leukaemia (AML) studies. We conducted a phase I/II open-label study (NCT04989335) to evaluate the safety and efficacy of Bis/Clo/Flu in relapsed/refractory AML. Twenty-one patients (median age: 47 years, 55% female) received Flu (10 mg/m2), Clo (30 mg/m2) and Bis (250 mg/m2) intravenously for 4 days. Sixteen had relapsed post-allogeneic stem cell transplantation, and six had extramedullary disease (EMD). Liver toxicity occurred in 10 patients but resolved. No significant cardiac toxicity was observed. Efficacy was assessable in 15 patients, while in six patients, it could not be evaluated due to early non-relapse mortality occurring within 30 days of treatment initiation, before the first post-treatment assessment. Six of the 15 patients responded: five achieved complete remission, and one with EMD achieved a partial remission, yielding a 40% response rate. Responses were transient, but six patients, including four undergoing second allo-HSCTs, proceeded to allo-HSCT within 1-3 months post-treatment. The Bis/Clo/Flu regimen demonstrated a tolerable safety profile and potential as a bridging therapy in high-risk, heavily pretreated AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Danylesko I, Shimoni A, Avigdor A, et al. Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study. Br J Haematol. 2025. PMID: 40746302. doi:10.1111/bjh.70035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。